open access

Vol 6, No 4 (2002)
REVIEV
Published online: 2002-10-18
Get Citation

Anti-Hypertensive Treatment - Importance of Cost-Effectiveness Analysis

Tomasz Grodzicki
Nadciśnienie tętnicze 2002;6(4):299-303.

open access

Vol 6, No 4 (2002)
REVIEV
Published online: 2002-10-18

Abstract

The rising costs of medical care force us to perform pharmacoeconomic analyses aiming at cost optimalisation. Whereas the therapy benefits can be easily calculated based on the results of treatment programmes, the cost analysis is more complicated, because it requires considering not only medical costs (e.g. drug, diagnostic procedures, hospitalisation and treatment of complications) but also additional costs. Pharmacoeconomic analyses performed in Poland show that the cost of antihypertensive treatment is about 14 thousand million zloty per year. This sum consists of costs for medical consultations (31%), hospitalisations (21%), diagnostic procedures (11%) and drugs (only 10%). Pharmacoeconomic analyses, conducted also in Poland, comparing costs and effectivness of older (enalapril) and modern (perindopril) ACE inhibitors evidently show the reduction of total costs and better antyhypertensive efficacy with the use of longacting ACE inhibitors. The results of these studies prove the need of employing a wider perspective in considering problems of antihypertensive treatment costs. The cost-effectiveness of antihypertensive therapy should be evaluated on the basis of total therapy costs and the clinical effects of treatment.

Abstract

The rising costs of medical care force us to perform pharmacoeconomic analyses aiming at cost optimalisation. Whereas the therapy benefits can be easily calculated based on the results of treatment programmes, the cost analysis is more complicated, because it requires considering not only medical costs (e.g. drug, diagnostic procedures, hospitalisation and treatment of complications) but also additional costs. Pharmacoeconomic analyses performed in Poland show that the cost of antihypertensive treatment is about 14 thousand million zloty per year. This sum consists of costs for medical consultations (31%), hospitalisations (21%), diagnostic procedures (11%) and drugs (only 10%). Pharmacoeconomic analyses, conducted also in Poland, comparing costs and effectivness of older (enalapril) and modern (perindopril) ACE inhibitors evidently show the reduction of total costs and better antyhypertensive efficacy with the use of longacting ACE inhibitors. The results of these studies prove the need of employing a wider perspective in considering problems of antihypertensive treatment costs. The cost-effectiveness of antihypertensive therapy should be evaluated on the basis of total therapy costs and the clinical effects of treatment.
Get Citation

Keywords

arterial hypertension; pharmacoeconomics; ACE inhibitors

About this article
Title

Anti-Hypertensive Treatment - Importance of Cost-Effectiveness Analysis

Journal

Arterial Hypertension

Issue

Vol 6, No 4 (2002)

Pages

299-303

Published online

2002-10-18

Bibliographic record

Nadciśnienie tętnicze 2002;6(4):299-303.

Keywords

arterial hypertension
pharmacoeconomics
ACE inhibitors

Authors

Tomasz Grodzicki

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl